795 related articles for article (PubMed ID: 15609230)
1. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.
Desprès P; Combredet C; Frenkiel MP; Lorin C; Brahic M; Tangy F
J Infect Dis; 2005 Jan; 191(2):207-14. PubMed ID: 15609230
[TBL] [Abstract][Full Text] [Related]
2. Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection.
Brandler S; Marianneau P; Loth P; Lacôte S; Combredet C; Frenkiel MP; Desprès P; Contamin H; Tangy F
J Infect Dis; 2012 Jul; 206(2):212-9. PubMed ID: 22551814
[TBL] [Abstract][Full Text] [Related]
3. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus.
Iglesias MC; Frenkiel MP; Mollier K; Souque P; Despres P; Charneau P
J Gene Med; 2006 Mar; 8(3):265-74. PubMed ID: 16308885
[TBL] [Abstract][Full Text] [Related]
4. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
[TBL] [Abstract][Full Text] [Related]
5. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge.
Karaca K; Bowen R; Austgen LE; Teehee M; Siger L; Grosenbaugh D; Loosemore L; Audonnet JC; Nordgren R; Minke JM
Vaccine; 2005 May; 23(29):3808-13. PubMed ID: 15893618
[TBL] [Abstract][Full Text] [Related]
6. Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.
Minke JM; Siger L; Cupillard L; Powers B; Bakonyi T; Boyum S; Nowotny N; Bowen R
Vaccine; 2011 Jun; 29(28):4608-12. PubMed ID: 21549780
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
[TBL] [Abstract][Full Text] [Related]
8. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
[TBL] [Abstract][Full Text] [Related]
9. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
[TBL] [Abstract][Full Text] [Related]
10. Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus.
Ledizet M; Kar K; Foellmer HG; Bonafé N; Anthony KG; Gould LH; Bushmich SL; Fikrig E; Koski RA
J Infect Dis; 2007 Dec; 196(12):1741-8. PubMed ID: 18190253
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy provided by a Recombinant Canarypox-Vectored Equine West Nile Virus vaccine against an experimental West Nile Virus intrathecal challenge in horses.
Siger L; Bowen R; Karaca K; Murray M; Jagannatha S; Echols B; Nordgren R; Minke JM
Vet Ther; 2006; 7(3):249-56. PubMed ID: 17039448
[TBL] [Abstract][Full Text] [Related]
12. Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease.
Alonso-Padilla J; de Oya NJ; Blázquez AB; Escribano-Romero E; Escribano JM; Saiz JC
Vaccine; 2011 Feb; 29(9):1830-5. PubMed ID: 21211580
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis.
Purtha WE; Myers N; Mitaksov V; Sitati E; Connolly J; Fremont DH; Hansen TH; Diamond MS
Eur J Immunol; 2007 Jul; 37(7):1845-54. PubMed ID: 17559174
[TBL] [Abstract][Full Text] [Related]
14. Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.
Throsby M; Ter Meulen J; Geuijen C; Goudsmit J; de Kruif J
Expert Rev Vaccines; 2007 Apr; 6(2):183-91. PubMed ID: 17408368
[TBL] [Abstract][Full Text] [Related]
15. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.
Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA
J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146
[TBL] [Abstract][Full Text] [Related]
16. A recombinant envelope protein vaccine against West Nile virus.
Ledizet M; Kar K; Foellmer HG; Wang T; Bushmich SL; Anderson JF; Fikrig E; Koski RA
Vaccine; 2005 Jun; 23(30):3915-24. PubMed ID: 15917113
[TBL] [Abstract][Full Text] [Related]
17. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
Chu JH; Chiang CC; Ng ML
J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
[TBL] [Abstract][Full Text] [Related]
18. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.
Huang CY; Silengo SJ; Whiteman MC; Kinney RM
J Virol; 2005 Jun; 79(12):7300-10. PubMed ID: 15919884
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.
Samina I; Havenga M; Koudstaal W; Khinich Y; Koldijk M; Malkinson M; Simanov M; Perl S; Gijsbers L; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2007 Nov; 25(49):8338-45. PubMed ID: 17977629
[TBL] [Abstract][Full Text] [Related]
20. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV).
Rosas CT; Tischer BK; Perkins GA; Wagner B; Goodman LB; Osterrieder N
Virus Res; 2007 Apr; 125(1):69-78. PubMed ID: 17241683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
